Peringatan Keamanan

Appears to be well-tolerated.

TA-NIC

DB05445

biotech investigational

Deskripsi

TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive reward associated with smoking.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data
Tidak ada data.

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17288232
    Goniewicz ML, Koszowski B, Czogala J, Zymelka A: New prospects of nicotine dependence treatment--vaccines. Przegl Lek. 2006;63(10):1114-8.
  • PMID: 15648190
    Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75.
  • PMID: 15270640
    Authors unspecified: Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines. 2004 Aug;3(4):386.
  • PMID: 8132774
    Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul